MANUFACTURING SERVICES AGREEMENT Among NABI BIOPHARMACEUTICALS, BIOTEST PHARMACEUTICALS CORPORATION And BIOTEST AGManufacturing Services Agreement • February 28th, 2008 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances) • New York
This MANUFACTURING SERVICES AGREEMENT, effective as of December 4, 2007 (the “Effective Date”), is entered into by and among NABI BIOPHARMACEUTICALS, a Delaware corporation (“Nabi”), having its principal place of business at 12276 Wilkins Avenue, Rockville, MD 20852, BIOTEST PHARMACEUTICALS CORPORATION, a Delaware corporation (“Biotest”), having its principal place of business at 5800 Park of Commerce Boulevard, Boca Raton, Florida 33487, and solely for purposes of Section 23(k), BIOTEST AG, a company organized under the laws of Germany (“Biotest AG”, and with Nabi and Biotest, each a “Party”, and collectively the “Parties”).
Nabi Biopharmaceuticals Boca Raton, Florida 33487 Employment Agreement Executed October 15, 2007 Effective as of August 16, 2007Nabi Biopharmaceuticals • February 28th, 2008 • Biological products, (no disgnostic substances) • Florida
Commencing immediately after the conclusion on August 16, 2007 (the “Effective Date”) of your successful interim six-month term as President and Chief Executive Officer of Nabi Biopharmaceuticals (“Nabi”), at Nabi’s request, you have agreed to continue to serve on an interim basis as President and Chief Executive Officer of Nabi. This Agreement sets forth the terms of such employment.
Page 1. DEFINITIONS/INTERPRETATION 1 1.1 Definitions 1 1.2 Interpretation 3 2. RECONCILIATION OF RIGHTS 4 2.1 The March 30 Agreement 4 2.2 Certain Rights to Improvements and Trademarks 5 2.3 Packaging and Labeling Requirements 5 3. TRANSITION...Termination Agreement • February 28th, 2008 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances) • New York
This TRANSITION/TERMINATION AGREEMENT (the “Agreement”) dated the 19th day of October 2007 with respect to the AGREEMENT TO DEVELOP, SUPPLY AND MARKET ATG – FRESENIUS NORTH AMERICA dated as of the 30th day of March, 2006 (the “March 30 Agreement”), is entered into by and between FRESENIUS BIOTECH GmbH, a company organized under the laws of the Federal Republic of Germany having a principal place of business at Am Haag 6-7, 82166 Graefelfing, Germany, hereinafter referred to as “FRESENIUS” and NABI BIOPHARMACEUTICALS, a corporation organized under the laws of Delaware having a principal place of business at 5800 Park of Commerce Blvd. N.W., Boca Raton, Florida 33487 USA, hereinafter referred to as “NABI”.
